Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.330
+0.010 (0.76%)
Aug 3, 2026, 12:48 PM EDT - Market open
Akebia Therapeutics Revenue
Akebia Therapeutics had revenue of $53.54M in the quarter ending March 31, 2026, a decrease of -6.61%. This brings the company's revenue in the last twelve months to $232.40M, up 25.69% year-over-year. In the year 2025, Akebia Therapeutics had annual revenue of $236.20M with 47.46% growth.
Revenue (ttm)
$232.40M
Revenue Growth
+25.69%
P/S Ratio
1.53
Revenue / Employee
$1,197,959
Employees
194
Market Cap
356.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 236.20M | 76.02M | 47.46% |
| Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
| Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
| Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
| Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
| Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
| Dec 31, 2019 | 335.00M | 127.26M | 61.26% |
| Dec 31, 2018 | 207.74M | 26.52M | 14.63% |
| Dec 31, 2017 | 181.23M | 179.69M | 11,706.32% |
| Dec 31, 2016 | 1.54M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 915.45M |
| Emergent BioSolutions | 676.80M |
| Organogenesis Holdings | 514.70M |
| Evolus | 301.79M |
| Canopy Growth | 203.89M |
| Kamada | 181.68M |
| Anika Therapeutics | 120.65M |
| SIGA Technologies | 93.78M |
AKBA News
- 4 hours ago - Akebia initiates ebribafusp basket trial - TheFly
- 5 days ago - Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Akebia announces VOICE trial met predefined stopping criteria - TheFly
- 4 weeks ago - U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA - GlobeNewsWire
- 6 weeks ago - Akebia Therapeutics Transcript: AGM 2026 - Transcripts
- 7 weeks ago - Akebia announces new Vafseo patent - TheFly
- 7 weeks ago - Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio - GlobeNewsWire